Current company Oliyai Consulting
Biotechnology Research · 21 employees · Founded 2022 · Atherton, United States
Oliyai Consulting Corporation (OCC) is a premier consulting firm serving the pharmaceutical and biotech industries, distinguished by the real-world expertise of its subject matter experts. We partner with 140+ clients from global pharma and biotech leaders to emerging startups to accelerate drug development from lead optimization through commercialization, with a core focus on Chemistry, Manufacturing, and Controls (CMC). Our 140+ seasoned professionals bring extensive and integrated experience in drug development, manufacturing, and commercialization, supported by strong connections to the global CRO/CDMO network. We deliver cost-effective, tailored solutions to complex strategic, scientific, technical, and operational challenges. Our expertise spans small molecules, peptides, biologics, ADCs, oligonucleotides (siRNA, mRNA, ASOs), cell therapies, and drug–device combination products. We support multiple delivery routes, including oral, injectable (IV, IM, SC, LAI), Intracerebroventricular (ICV), intravitreal, inhalation, nasal, ophthalmic, intrathecal, and pediatric formulations. We provide phase-appropriate regulatory, quality, and compliance support and are actively involved in numerous IND, IMPD, NDA, MAA, and BLA submissions. Beyond CMC, we offer expertise in preclinical development, patent litigation support, and organizational development. Founded by Dr. Reza Oliyai, a pharmaceutical leader with over 30 years of industry experience, OCC is built on a legacy of innovation and operational excellence. As Senior Vice President at Gilead Sciences, Dr. Oliyai led the development of more than 300 drug candidates and the commercialization of over 25 products — experience that continues to guide OCC’s mission to help clients navigate complexity and achieve success. To learn more please contact Reza Oliyai at r•••••@oliyaiconsulting.com.